Consistent with the heavily documented finding that CD28-containing CAR T-cells elicit stronger anti-tumor responses with increased cytokine release in vitro and in vivo (8, 85–92), CAR T-cells incorporating both CD28 and CD3 co-stimulatory domains had superior resistance to Tregs compared to CAR T-cells containing only a CD3 domain (93). This evidence concerns the gene CD28 and neoplasm.